Radiomics of Prostate Cancer (PET)

One of our ongoing efforts is to perform radiomics (texture/heterogeneity quantification) for the exciting prostate cancer tracer, PyL. Developed by the group of Dr. Martin Pomper, PyL (a PSMA-targeted PET imaging agent; see video below) is now licensed to Progenics which works closely with our division to further establish clinical use of this tracer.